Endo Pharmaceuticals

Results: 21



#Item
1QUALITEST PHARMACEUTICALS TO PAY $39 MILLION TO RESOLVE FALSE LABELING ALLEGATIONS The National Association of Medicaid Fraud Control Units (NAMFCU) announced on December 16, 2015 that 47 states and the federal governmen

QUALITEST PHARMACEUTICALS TO PAY $39 MILLION TO RESOLVE FALSE LABELING ALLEGATIONS The National Association of Medicaid Fraud Control Units (NAMFCU) announced on December 16, 2015 that 47 states and the federal governmen

Add to Reading List

Source URL: www.namfcu.net

Language: English - Date: 2016-03-31 16:45:51
2Valeant ups Salix bid to $11.11B and Endo ends quest (Update)

Valeant ups Salix bid to $11.11B and Endo ends quest (Update)

Add to Reading List

Source URL: medicalxpress.com

Language: English - Date: 2015-05-28 13:02:04
3Case Study – Mobile Endo Pharmaceuticals moves ahead with Morse mobile solution

Case Study – Mobile Endo Pharmaceuticals moves ahead with Morse mobile solution

Add to Reading List

Source URL: www.barcoding.com

Language: English - Date: 2014-12-17 21:10:54
4PhRMA Code on Interactions with Healthcare Professionals External Verifications The PhRMA Code on Interactions with Healthcare Professionals states that “companies are encouraged to seek external verification periodica

PhRMA Code on Interactions with Healthcare Professionals External Verifications The PhRMA Code on Interactions with Healthcare Professionals states that “companies are encouraged to seek external verification periodica

Add to Reading List

Source URL: www.phrma.org

Language: English - Date: 2014-11-13 12:01:01
5(lidocaine and tetracaine) Topical Patch idiopathic methemoglobinemia, and infants under the age of twelve months who are receiving treatment with methemoglobin-inducing agents. • Very young patients or patients with

(lidocaine and tetracaine) Topical Patch idiopathic methemoglobinemia, and infants under the age of twelve months who are receiving treatment with methemoglobin-inducing agents. • Very young patients or patients with

Add to Reading List

Source URL: www.galen-pharma.com

Language: English - Date: 2014-03-28 10:14:04
6MIHARI Project Year 5 Medical Information for Risk Assessment Initiative Chieko Ishiguro, Ayumi Endo, Kazuhiro Matsui, Shinichi Watanabe Office of Safety I, Pharmaceuticals and Medical Devices Agency (PMDA) – Tokyo, JA

MIHARI Project Year 5 Medical Information for Risk Assessment Initiative Chieko Ishiguro, Ayumi Endo, Kazuhiro Matsui, Shinichi Watanabe Office of Safety I, Pharmaceuticals and Medical Devices Agency (PMDA) – Tokyo, JA

Add to Reading List

Source URL: www.pmda.go.jp

Language: English - Date: 2014-12-02 01:39:29
7Drug Use Study of Heparin using Japanese Claim Data of Inpatients Maki Noguchi, Ayumi Endo, Kaori Yamada, Kazuhiro Matsui, Shinichi Watanabe Office of Safety I, Pharmaceuticals and Medical Devices Agency (PMDA) – Toky

Drug Use Study of Heparin using Japanese Claim Data of Inpatients Maki Noguchi, Ayumi Endo, Kaori Yamada, Kazuhiro Matsui, Shinichi Watanabe Office of Safety I, Pharmaceuticals and Medical Devices Agency (PMDA) – Toky

Add to Reading List

Source URL: www.pmda.go.jp

Language: English - Date: 2014-12-02 01:39:30
8Kentucky Medicaid Pharmacy 3Q2010 Labeler ID Labeler Name

Kentucky Medicaid Pharmacy 3Q2010 Labeler ID Labeler Name

Add to Reading List

Source URL: kyportal.magellanmedicaid.com

Language: English - Date: 2011-07-14 14:21:31
9Kentucky Medicaid Pharmacy 3Q2011 Active Labelers List Labeler ID Labeler Name

Kentucky Medicaid Pharmacy 3Q2011 Active Labelers List Labeler ID Labeler Name

Add to Reading List

Source URL: kyportal.magellanmedicaid.com

Language: English - Date: 2012-01-17 15:13:20
10Kentucky Medicaid Fee-For-Service Pharmacy 1Q2012 Active Labelers List Labeler ID[removed]00004

Kentucky Medicaid Fee-For-Service Pharmacy 1Q2012 Active Labelers List Labeler ID[removed]00004

Add to Reading List

Source URL: kyportal.magellanmedicaid.com

Language: English - Date: 2012-05-24 16:48:30